TissGeneSummary for ACY3 |
Gene summary |
Basic gene information | Gene symbol | ACY3 |
Gene name | aspartoacylase (aminocyclase) 3 | |
Synonyms | ACY-3|HCBP1 | |
Cytomap | UCSC genome browser: 11q13.2 | |
Type of gene | protein-coding | |
RefGenes | NM_080658.1, | |
Description | HCV core-binding protein 1N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming)acylase IIIaminoacylase-3aspartoacylase-2hepatitis C virus core-binding protein 1 | |
Modification date | 20141207 | |
dbXrefs | MIM : 614413 | |
HGNC : HGNC | ||
Ensembl : ENSG00000132744 | ||
HPRD : 12422 | ||
Vega : OTTHUMG00000167283 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ACY3 | |
BioGPS: 91703 | ||
Pathway | NCI Pathway Interaction Database: ACY3 | |
KEGG: ACY3 | ||
REACTOME: ACY3 | ||
Pathway Commons: ACY3 | ||
Context | iHOP: ACY3 | |
ligand binding site mutation search in PubMed: ACY3 | ||
UCL Cancer Institute: ACY3 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Kidney | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | KIRC,KIRP,KICH | |
Reference showing the relevant tissue of ACY3 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for ACY3 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
KICH | -2.668920768 | 4.116243232 | -6.785164 | 1.06E-16 | 3.49E-15 |
LUAD | 0.550492129 | -1.610085458 | 2.160577586 | 2.47E-14 | 2.34E-13 |
PRAD | -1.712858999 | -0.692891691 | -1.019967308 | 0.000963 | 0.003118617 |
KIRP | 2.963563357 | 5.442691482 | -2.479128125 | 0.000113 | 0.000378694 |
LIHC | 3.940917232 | 5.270791232 | -1.329874 | 8.08E-05 | 0.000285305 |
Top |
TissGene-miRNA for ACY3 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for ACY3 |
TissGeneSNV for ACY3 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.A307V | LUAD | 1 |
p.L115Q | LUAD | 1 |
p.M220I | LUAD | 1 |
p.A222D | SARC | 1 |
p.E285K | SKCM | 1 |
p.P181L | SKCM | 1 |
p.V293I | LUSC | 1 |
p.R13H | UCEC | 1 |
p.A56P | HNSC | 1 |
p.S266N | UCEC | 1 |
p.P82T | BLCA | 1 |
p.Y279C | STAD | 1 |
p.D204N | SKCM | 1 |
p.E207K | SKCM | 1 |
p.P55R | BLCA | 1 |
p.Q42H | BLCA | 1 |
p.Q98K | SKCM | 1 |
p.A39E | SKCM | 1 |
p.P280S | LUAD | 1 |
p.C140Y | LIHC | 1 |
p.N121S | UCEC | 1 |
p.E163K | HNSC | 1 |
p.A39T | SKCM | 1 |
p.A128V | KIRP | 1 |
p.D269G | LIHC | 1 |
p.R233C | PRAD | 1 |
p.P309T | HNSC | 1 |
p.C152X | COAD | 1 |
p.Q184H | BLCA | 1 |
p.Q98L | LUSC | 1 |
p.N166S | SKCM | 1 |
p.P216S | BLCA | 1 |
p.M195I | BLCA | 1 |
p.V305M | SKCM | 1 |
p.V65E | STAD | 1 |
p.A294T | BLCA | 1 |
p.F262L | ESCA | 1 |
p.R141H | GBM | 1 |
Top |
TissGeneCNV for ACY3 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ACY3 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for ACY3 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ACY3 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ACY3 |
TissGeneDrug for ACY3 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
DB00128 | L-Aspartic Acid | Small molecule | Approved|Nutraceutical |
Top |
TissGeneDisease for ACY3 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0007134 | Renal Cell Carcinoma | 1 | BeFree |
umls:C0023903 | Liver neoplasms | 1 | BeFree |
umls:C0027819 | Neuroblastoma | 1 | BeFree |
umls:C0700095 | Central neuroblastoma | 1 | BeFree |
umls:C2239176 | Liver carcinoma | 1 | BeFree |